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INTRODUCTION:  Gastrointestinal  stromal  tumors  (GISTs)  are  rare intra-abdominal  tumors  arising  from
mesenchymal  stromal  cells.  EGISTs  are  mesenchymal  tumors  that  originate  outside  the  GI tract  and  tend
to  have  similar  characteristics  to  GISTs.  To the  best of  our knowledge,  few  cases  of long  standing  recurrent
EGIST  have  been  reported.
PRESENTATION OF  CASE:  We  present  the  case  of  a rare recurrent  EGIST  in  the  mesentery  of  a
39  year  old  female  patient.  The  tumor  was symptomatic  at the  time  of  complaint  and  measured
8.4  cm  × 7.7  cm  ×  7.6  cm.  Histological  analysis  revealed  a  spindled  pattern  with  fusiform  cells  arranged  in
long  fascicles  and  little  atypia.  Immunochemistry  showed  positivity  for  CD117  and  was  negative  for  CD34,
S-100,  Desmin,  and  MSA.  B-catenin  was  weakly  positive.  A  Ki-67  staining  shows  approximately  5% posi-
tivity  revealing  a low  proliferative  rate.  The  patient  was  doing well  postoperatively  and  was  discharged
on  400  mg  imanitib  regimen.
DISCUSSION:  While  GISTs  are the  most  common  tumors  of the  GI  tract,  recurrent  EGISTs  of  the  mesentery
are  extremely  rare.  Factors  that  indicate  poor  prognosis  include  tumor  size  greater  than  5  cm,  mitotic  rate
greater  than  1–5/10  HPF,  presence  of tumor  necrosis  or metastasis  and  most  recently  the c-kit  mutation.
Our  patient  had  a very  long  time  between  recurrence  of disease.
CONCLUSION: The  current  literature  on  EGISTs  is  limited.  Our  patient  presents  a very  interesting  case  due
een  d
sevieto  the time  elapsed  betw
Published by El
. Introduction
Gastrointestinal stromal tumors (GISTs) are rare intra-
bdominal tumors arising from mesenchymal stromal cells and
ccount for approximately 5% of GI malignancies.1 There are
pproximately 3300–4350 GISTs diagnosed a year and 150 of those
re classiﬁed as EGISTs (extra-gastrointestinal stromal tumors).1,2
GISTs are mesenchymal tumors that originate outside the GI tract
nd tend to have similar characteristics to GISTs. EGISTs account
or less than 1% of all GI malignancies.1 Here we present a case of
ecurrent multiple EGIST of the mesentery.
. Presentation of caseWe report the case of a 39 year old African American female
resented to the emergency room with the chief complaint of
ow back pain superior to the rectum that radiated down the leg
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accompanied by nausea. A computer tomography (CT) scan
was performed and revealed a cystic mass adjacent to the
mid transverse colon, but not incorporated in it, measuring
8.4 cm × 7.7 cm × 7.6 cm and an adjacent solid nodule enhancing
the soft tissue measuring 2.9 cm × 1.2 cm (see Fig. 1).
The patient’s past medical and surgical history were pertinent
for an appendectomy, three cesarean sections and a hysterec-
tomy. The patient also reported having undergone prior “intestinal”
surgery for a similar complaint 17 years prior but denied receiving
any adjuvant therapy. There was  no family history of cancer. Of
note, she underwent a colonoscopy in July 2011 for these com-
plaints but her workup did not reveal a malignancy. Pertinent
physical ﬁndings were a large mobile right upper quadrant mass
with potential involvement of the transverse colon. The ﬁndings
were highly suggestive of a malignant lesion.
On August 25th, 2011 the patient underwent surgery for an “en
bloc” resection including an open extended right hemicolectomy,
resection of the two  mesenteric masses and creation of anileo-colic
anastomosis. There was  no evidence of peritoneal metastasis or
ascites and the liver appeared normal. The ﬁrst mass was approx-
Open access under CC BY-NC-ND license.imately 10 cm in size and the second mass approximately 6 cm
deeper with no other adenopathy or masses identiﬁed. The tumor
appeared to be densely adherent to the wall of the transverse colon
and to the hepatic ﬂexure. The tumor could not be separated from
r CC BY-NC-ND license.
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FFig. 1. CT demonstrates cystic mass measuring 8.4 cm ×7.7 cm ×7.6 cm an
he colon wall. Both masses were resected while maintaining per-
usion of the gut. Evidence of a prior small bowel resection was  also
ound conﬁrming the patient’s past surgical history.
The patient had no post-operative complications and was  dis-
harged on postoperative day ﬁve. The patient returned with a
mall inferior wound infection, which resolved with local care and
as successfully treated with oral mefronidazole for a Clostridium
ifﬁcile colitis. She is currently receiving adjuvant therapy with
aily 400 mg  imanitib mesylate which has been recommended for
hree years.
Post-operative gross examination is seen in Fig. 2. Microscopic
issue examination of the tumor revealed multiple nodules with the
argest measuring 8.5 cm × 8 cm and 5 additional smaller tumors of
xtra gastrointestinal (soft tissue) stromal tumor (EGIST). Based on
ytology, the large variable cellular tumor had a spindled pattern
ith fusiform cells arranged in long fascicles and little atypia. The
itotic count is 2–3 MF/50 HPF. While the tumor demonstrates
reas of infarction, there is no evidence of tumor necrosis. The seg-
ent of the small bowel and colon are uninvolved by the tumor
nd showed various serosal adhesions. Thirty-eight reactive lymph
odes were resected but all were negative for cancer. Immunohis-
ochemical study revealed positive staining for CD117 but negative
or CD34, S-100, Desmin, and MSA. B-catenin was weakly positive.
 Ki-67 staining shows approximately 5% positively revealing a low
roliferative rate. Fig. 3 demonstrates positive staining for CD117
ig. 2. EGIST abutting colonic wall showing no involvement of the colonic wall.djacent solid nodule enhancing the soft tissue measuring 2.9 cm × 1.2 cm.
and B-catenin, a low proliferative rate for Ki-67 staining and a H&E
staining of the tumor cells. Fig. 4 shows the microscopic image of
EGIST grossly abutting colonic wall but demonstrating there is no
involvement of the colonic wall.
3. Discussion
The most common sites for GISTs are the stomach and the small
intestine. The more distally a GIST is found in the GI tract, the
worse the prognosis tends to be.3 EGISTs are most commonly found
in the omentum, mesentery and retroperitoneum but have also
been reported in the pancreas, gallbladder, retro-vaginal septum,
liver, abdominal wall, periversical tissue, pharynx and posterior
mediastinum.1–7 Based on reports, EGISTs tend to be much larger
than GISTs and vary from 2.1 to 33 cm in diameter.3,7,8
3.1. Origin
EGIST is thought to arise from a common precursor of the inter-
stitial cells of Cajal (ICC) because they both express CD117 (cluster
of differentiation 117, a protein transcribed from the c-kit gene).
CD117 is a transmembrane receptor protein found in hematopoi-
etic stem cells, mast cells, germ cells and melanocytes.7,8 ICCs are
physiologically found in the myoenteric plexus of the muscularis
propia of the smooth muscle in the tubular GI tract and are thought
of as the pacemaker cells of the intestinal smooth muscle due to
their association with peristalsis.4 The literature presents some
controversy on the origin of EGISTs. One hypothesis supports the
idea that GISTs and EGISTs both arise from a common precursor of
the ICCs and smooth muscle cells due to the expression of CD117
while another hypothesis asserts that EGISTs are simply mural
GISTs with extensive extramural growth that eventually lost con-
nection with the gut wall.8 The second hypothesis was  suggested
due to the existence of primary EGISTs because ICC cells are not
found outside the GI tract and thus it would be impossible for them
to give rise to these tumors unless the tumors were originally in
contact with the gut wall.
3.2. Clinical presentationMost  patients diagnosed with EGISTs present with symptoms of
abdominal pain, an abdominal mass or GI bleeding. Less common
symptoms include anorexia, dysphagia, obstruction, perforation
and fever.1 There is no predilection based on gender but there is
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&E  stain of tumor cells is seen in (D).
or age. Most patients are diagnosed beyond middle age but EGISTs
ave been reported in individuals in their twenties.2 EGISTs are
ypically visualized by CT or MRI.
.3. Treatment
The current and widely accepted treatment for both GISTs
nd EGISTs is complete resection.1,3,7 Survival is correlated with
he completeness of the resection and fortunately since stro-
al tumors do not usually invade adjacent tissue, wide margins
re not necessary. “En bloc” resection is recommended if con-
iguous organs are involved. The most important thing to avoid
ntra-operatively is tumor rupture as it increases the chances
f peritoneal recurrence.1 Recurrent disease is common thus
Fig. 4. EGIST abuttin17 (A) and B-catenin (B) but Ki-67 stain shows low proliferative rate (C). A standard
adjuvant  therapy is recommended as well as strict follow up.
Currently, imatinib and sunitinib, both selective tyrosine kinase
inhibitors, are being used for those with metastatic or recurrent
disease.1,5,6 Other drugs such as adriamycin, doxorubicin, dacr-
bzine and mitoxcintrone have been used but there is little published
literature assessing the level of effectiveness.1
3.4. Pathology (prognosis factors)
Approximately two-thirds of EGISTs turn out to be malignant,
thus it is important to identify a list of prognostic factors for the
disease despite its rarity. Based on cytology, EGISTs are classiﬁed
into three cell types; spindle cell, epithelioid/round cell type or
mixed. Epithelioid cell type EGISTs tend to comprise most the KIT
g colonic wall.
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egative EGISTs but neither cell type is predictive of malignancy
citation). There is no accepted cancer staging system but the fol-
owing factors have shown to be most useful in indicating poor
rognosis: size (>5 cm), mitotic rate (<1–5/10 HPF), presence of
umor necrosis or metastasis and most recently the c-kit mutation
usually in exon 11).1,9 Recent gene proﬁling has revealed other
seful proteins that could aid in diagnosis of EGISTs. The c-kit gene
as long been used to as a useful test for identifying GISTs. How-
ver, the increasing numbers of KIT negative EGISTs inspired the
earch for other identifying molecular markers common to EGISTs.
latelet derived growth factor receptor alpha (PDGRF-) has been
dentiﬁed in EGISTs that are resistant to imanitib.10 In addition,
KC , an isotype of PKC (protein kinase C), has been identiﬁed
s a new marker for GISTs and is found in both KIT positive and
IT negative tumors. Lastly, DOG1, a membrane protein associ-
ted with the calcium dependent chloride channel is upregulated
n 90% of GISTs and antibodies have already been developed against
t.6
. Conclusion
Despite complete resection, 50% of patients have recurrent dis-
ase within 2 years.11 We  believe that the cyst removed from our
atient was recurrence of the disease she had 17 years prior. This
ay be considered a long time for disease recurrence as well as clas-
iﬁed as minimally aggressive in growth rate. As recommended by
iner and Raut, our patient has started a 400 mg daily treatment
f imatinib mesylate, which is currently the adjuvant therapy of
hoice for those with recurrent GISTs disease.
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